OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Phillips on Ongoing Research in High-Risk MCL

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Dr Mehta on Radiation Oncology Innovations in Prostate Cancer

March 28th 2024

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.

Dr Kummar on the Evaluation of Rezatapopt in Advanced Solid Tumors

March 27th 2024

Shivaani Kummar, MD, FACP, discusses the evaluation of rezatapopt in patients with advanced solid tumors.

Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCL

March 27th 2024

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Dr Xu on Ongoing Research Initiatives in ccRCC

March 27th 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Dr Koehne on Efforts to Overcome CAR T-Cell Resistance in Hematologic Malignancies

March 27th 2024

Guenther Koehne, MD, PhD, discusses research efforts to overcome resistance to CAR T-cell therapy in hematologic malignancies.

Dr Villa on the Incidence of Oral Toxicities in Patients With Head and Neck Cancer

March 27th 2024

Alessandro Villa, DDS, PhD, MPH, discusses the incidence of oral toxicities in patients with head and neck cancer.

Dr Mikhael on Unmet Needs to Be Addressed in Multiple Myeloma

March 27th 2024

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Dr Richardson on Escalating Rates of Uterine Cancer Among Asian Americans

March 27th 2024

Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.

Dr Mehta on the Advantages of MRI-Guided Adaptive Radiotherapy in Cancer Care

March 26th 2024

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.

Dr Olivares on the Use of Focal Therapy in Localized Prostate Cancer

March 26th 2024

Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.

Dr Koo on PSMA PET Imaging in Prostate Cancer

March 26th 2024

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

Dr Dizon on the Prevalence of Sexual Challenges in Patients With Breast Cancer

March 26th 2024

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Dr Konecny on the MIRASOL trial and Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

March 26th 2024

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Dr Finkelstein on the Significance of the 2024 ACRO Summit

March 26th 2024

Steven E. Finkelstein, MD, DABR, FACRO, on advancing radiation oncology and updates from the 2024 ACRO Summit.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Dr Spratt on Metastasis-Directed Therapy and Hypofractionation in Prostate Cancer

March 26th 2024

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL

March 25th 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma

March 25th 2024

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Dr Spratt on the Use of Radiation in Low– and High-Risk Prostate Cancer

March 22nd 2024

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.